Autologous MUC1-specific Th1 effector cell immunotherapy induces differential levels of systemic TReg cell subpopulations that result in increased ovarian cancer patient survival

Adoptive T cell immunotherapy using autologous lymphocytes is a viable treatment for patients with cancer and requires participation of Ag-specific CD4 and CD8 T cells. Here, we assessed the immunotherapeutic effects of autologous MUC1 peptide-stimulated CD4(+) effector cells following adoptive tran...

Description complète

Détails bibliographiques

Publié dans:	Clinical immunology (Orlando, Fla.). - 1999. - 133(2009), 3 vom: 15. Dez., Seite 333-52
Auteur principal:	Dobrzanski, Mark J (Auteur)
Autres auteurs:	Rewers-Felkins, Kathleen A, Quinlin, Imelda S, Samad, Khaliquzzaman A, Phillips, Catherine A, Robinson, William, Dobrzanski, David J, Wright, Stephen E
Format:	Article en ligne
Langue:	English
Publié:	2009
Accès à la collection:	Clinical immunology (Orlando, Fla.)
Sujets:	Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, Non-P.H.S. Antigens, CD CA-125 Antigen CTLA-4 Antigen CTLA4 protein, human Cytokines FOXP3 protein, human plus... Forkhead Transcription Factors MUC1 protein, human Mucin-1 Leukocyte Common Antigens EC 3.1.3.48